CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and frequent chemoresistance.
• Claudin-1 (CLDN1), a tight junction protein, is underexpressed in a majority of TNBC cases and linked to poorer patient outcomes.
• The specific role of CLDN1 in TNBC chemosensitivity remains largely unexplored.

Purpose of the Study:

• To investigate the correlation between CLDN1 expression levels and prognosis in TNBC patients.
• To determine the impact of CLDN1 expression on the sensitivity of TNBC cells to common chemotherapeutic agents.
• To evaluate CLDN1 as a potential predictive marker for chemotherapy response in TNBC.

Main Methods:

• Clinical data analysis to correlate CLDN1 expression with TNBC patient prognosis.
• Assessment of TNBC cell line sensitivity to 5-fluorouracil (5-FU), paclitaxel (PTX), and doxorubicin (DOX) based on CLDN1 expression levels.
• Utilized RNA interference and stable overexpression models to manipulate CLDN1 expression.

Main Results:

• Low CLDN1 expression was significantly correlated with a poorer prognostic outcome in TNBC patients.
• Increased CLDN1 expression in TNBC cell lines enhanced their sensitivity to 5-FU, PTX, and DOX.
• CLDN1 expression levels directly influenced the chemosensitivity of TNBC cells.

Conclusions:

• CLDN1 plays a significant role in determining the chemosensitivity of triple-negative breast cancer cells.
• CLDN1 is a potential predictive biomarker for chemotherapy response in TNBC patients.
• Targeting CLDN1 expression could lead to novel therapeutic strategies to improve TNBC treatment outcomes.